Development of a novel senescence-related gene signature to predict clinical outcomes, immune landscape, and chemotherapeutic sensitivity in oral squamous cell carcinoma

An Wang ^1,2, Na Xiao ^1,3, Hong Wang ¹

⁰Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanjing Medical University, Jiangsu, China.

Head & Neck +

|

February 21, 2024

View abstract on PubMed

Summary

A new gene signature aids in predicting oral squamous cell carcinoma (OSCC) outcomes and treatment response. This discovery offers valuable insights for OSCC prognostication and personalized therapy strategies.

Area Of Science

Oncology
Molecular Biology
Genetics

Background

Cellular senescence is crucial in cancer development and treatment.
Developing predictive tools for oral squamous cell carcinoma (OSCC) is essential.

Purpose Of The Study

To create a novel senescence-related genes (SRGs)-derived signature for OSCC prognostication.
To predict therapeutic response in OSCC patients using SRGs.

Main Methods

Established an OSCC-specific SRG prognostic signature using Cox regression and LASSO analysis.
Developed a SRG nomogram integrating clinicopathological parameters.
Validated SRG signature functions through in vitro gene knockdown and analyzed its correlation with immune status and drug sensitivities.

Main Results

The SRG signature and nomogram demonstrated satisfactory prognostic performance across independent cohorts.
CDK1 knockdown successfully induced a senescence phenotype in vitro.
SRG signature scores correlated negatively with tumor-infiltrating immune cells and predicted chemotherapeutic drug sensitivities.

Conclusions

The developed SRG-derived signature and nomogram are effective predictors for OSCC prognosis.
These tools can guide therapeutic strategies and predict patient response to chemotherapy.

Keywords:

CDK1 chemotherapeutic response immune landscape oral squamous cell carcinoma senescence‐related gene signature